Spitz tumors represent a group of melanocytic neoplasms that typically affect young individuals. Microscopically, the lesions are composed of cytologically distinct spindle and epithelioid melanocytes, with a range in the architectural display or the cells, their nuclear features, and secondary epidermal or stromal changes. Recently, kinase fusions have been documented in a subset of Spitz tumors, but there is limited information on the clinical and pathologic features associated with those lesions. Here, we report a series of 17 patients (9 male, 8 female) with spitzoid neoplasms showing ALK fusions (5 Spitz nevi and 12 atypical Spitz tumors). The patients' ages ranged from 2 years to 35 years (mean = 17 y; median = 16 y). Most lesions were located on the lower extremities and presented clinically as polypoid nodules. All tumors were compound melanocytic proliferations with a predominant intradermal growth. Tumor thickness ranged from 1.1 to 6 mm (mean = 2.9 mm; median = 2.5 mm). The most characteristic histopathologic feature of the tumors (seen in all but 2 lesions) was a plexiform dermal growth of intersecting fascicles of fusiform melanocytes. All but 2 tumors were amelanotic. All tumors were strongly immunoreactive for ALK. The ALK rearrangements were confirmed in all cases by fluorescence in situ hybridization (FISH), and the fusion partner was determined by quantitative polymerase chain reaction as TPM3 (tropomyosin 3) in 11 cases and DCTN1 (dynactin 1) in 6 cases. None of the 8 tumors that were analyzed by FISH for copy number changes of 6p, 6q, 9p, or 11q met criteria for melanoma. Two patients underwent a sentinel lymph node biopsy, and in both cases melanocyte nests were found in the subcapsular sinus of the node. Array comparative genomic hybridization of these 2 tumors revealed no chromosomal gains or losses. In conclusion, our study revealed that Spitz nevi/tumors with ALK rearrangement show a characteristic plexiform morphology and that ALK im-munohistochemistry and FISH enable the accurate identification of this morphologic and genetic distinct subset of spitzoid neoplasms.
S pitzoid melanocytic neoplasms include Spitz nevi (benign tumors), so-called "atypical Spitz tumors" (tumors of uncertain malignant potential), and "spitzoid" melanomas (malignant tumors, with metastasizing and lethal potential 1 ). They remain a problem area in the field of dermatopathology because of the difficulty in distinguishing the relatively more common indolent lesions from the rare metastasizing and lethal spitzoid melanoma. However, significant progress has been made over the past decade regarding cytogenetic and/or molecular alterations of these tumors. [2] [3] [4] [5] [6] [7] A number of subsets of Spitz tumors have been identified with distinct, clinical, pathologic, and genetic features. They include the HRAS-mutant sclerosing Spitz nevi, 2 the BAP1 loss Spitz tumors, [7] [8] [9] and the spitzoid melanomas with homozygous deletions of p16. 6 An important milestone in our understanding of Spitz tumors is the recent discovery that some of them harbor gene fusions involving receptor tyrosine kinases ALK, ROS1, NTRK1, and RET or the serine-threonine kinase BRAF. 10 Such gene rearrangements were found in 72 of 140 (51.4%) spitzoid neoplasms. Fourteen of these 140 (10%) spitzoid neoplasms showed ALK fusions. All kinase fusions were mutually exclusive and occurred only in tumors without HRAS mutations or loss of BAP1. Kinase fusions were detected across the entire spectrum of Spitz lesions (benign Spitz nevi, atypical Spitz tumors, and rare spitzoid melanomas), which suggests that the fusions likely occur early in the pathogenesis of the tumors and are per se not sufficient for malignant transformation. This observation is analogous to that of mutations in oncogenes (such as BRAF, NRAS, GNAQ, and GNA11) commonly found in melanocytic neoplasms. 4, 7, 11, 12 Currently, it is unknown whether or not any of the translocation-associated Spitz tumors have distinct clinical and/or pathologic features. It is also unknown whether the presence or absence of a kinase fusion of a particular type is associated with a more indolent or aggressive clinical course. In this study, we document clinical findings and describe the spectrum of microscopic features associated with Spitz nevi and atypical Spitz tumors carrying ALK fusions.
METHODS

Case Selection
Eight cases were from the personal consultation files of one of the authors (K.J.B.), 8 cases from another author (H.K.), and 1 case from a third author (L.C.). Only cases diagnosed as a Spitz nevus or an "atypical Spitz tumor," but not tumors reported as or favored to be malignant melanomas, were included in this series. Thirteen of the 17 analyzed tumors were included in the initial study reporting kinase fusions in spitzoid tumors 10 ; cases 2, 3, 10, and 11 have not been previously reported.
Light Microscopic Analysis
The following histopathologic parameters were recorded: polypoid silhouette, ulceration, epidermal hyperplasia, tumor thickness, anatomic (Clark) level, tumor mitotic rate (number of mitotic figures in dermal or subcutaneous melanocytes per mm 2 ), plexiform growth pattern, inflammation, and the presence of melanin pigment.
Immunohistochemistry
Immunohistochemical studies were conducted using 5-mm-thick unstained sections of formalin-fixed, paraffinembedded archival material. We used the ALK antibody (clone D5F3) from Cell Signaling (Danvers, MA) on a Discovery Ultra instrument with a multimer/DAB detection system (Ventana Medical Systems Inc., Tucson, AZ) with appropriate negative and positive controls.
Quantitative Polymerase Chain Reaction and Sanger Sequencing
RNA was extracted from 20-mm-thick formalinfixed, paraffin-embedded tissue sections (High Pure miRNA Isolation Kit; Roche) and was reverse-transcribed with random hexamer primers using the Transcriptor First Strand cDNA Synthesis Kit (Roche). The ALK fusion partners were determined by quantitative polymerase chain reaction (PCR) using break-point spanning primers reported previously. 10 Specific PCR amplicons were only detected with the appropriate combination of primers and template and not with negative controls. The nucleotide sequence of the PCR products was confirmed by Sanger sequencing.
Fluorescence In Situ Hybridization
Two sets of fluorescence in situ hybridization (FISH) tests were performed. To confirm the ALK fusions, a commercially available break-apart probe was used according to the manufacturer's protocol (Abbott Molecular, Des Plaines, IL). The probes were hybridized on 5-mm-thick tissue sections, and the number and localization of the hybridization signals was assessed in a minimum of 100 interphase nuclei with well-delineated contours. At least 50% of neoplastic cells had to show a split signal to report a rearrangement of a kinase.
The so-called "melanoma FISH test" was used in the workup of some atypical Spitz tumors to identify chromosomal copy number changes typical of melanoma (Abbott Molecular). In this test, a set of 4 probes targeting Ras responsive element-binding protein-1 (VysisLSI 
RREB1-Spectrum
Red), myeloblastosis (VysisLSI MYB-S Gold), cyclin D1 or chromosome 11q (VysisLSI CCND1-Spectrum Green), and centromeric enumeration probe control for chromosome 6 (VysisLSI CEP6-Spectrum Aqua) was initially used, followed by a probe set assessing aberrations of chromosome 9p (VysisLSI CDKN2A/CEP 9 FISH probe kit). The protocol used for these FISH tests has previously been described. [13] [14] [15] A lesion was considered as having a positive FISH result if any of the following criteria were met: (1) gain in 6p25(RREB1) relative to CEP6 >55% or gain in 6p25(RREB1) >29%; (2) loss in 6q23(MYB) relative to CEP6 >40%; (3) gain in 11q13(CCND1) >38% or homozygous loss of 9p(CDNK2A) in >30% of the tumor cells.
aCGH Tumor and reference DNA were differentially labeled with dCTP-Cy5 and dCTP-Cy3 (GE Healthcare, Piscataway, NJ) using a Bioprime Array CGH Genomic Labeling Kit (Invitrogen, Carlsberg, CA) according to the manufacturer's instructions. Genome-wide analysis of DNA copy number changes was conducted using an oligonucleotide array containing 180k probes according to the manufacturer's protocol (SurePrint G3 Human CGH Microarray Kit, 1 Â 180k; Agilent, Santa Clara, CA). Slides were scanned using Agilent's microarray scanner G2505B and analyzed using Agilent Genomic Workbench. 
RESULTS
Clinical Findings
The group of individuals with ALK-fusion Spitz nevi or tumors included 9 male and 8 female patients. Their ages ranged from 2 to 35 years (mean = 17 y; median = 16 y). None of them reported a family history of melanoma. None of the clinical lesions was suspected to be melanoma. All were solitary lesions. They were removed as "irritated nevus," "atypical nevus," "angioma," or "verruca." Six lesions were located on the lower extremities, 4 were from the trunk and buttocks, 3 were from the head and neck region, and 2 lesions were located on the upper extremities ( Table 1 ). The anatomic site was not specified in 2 cases. Five tumors were reported as Spitz nevus and 12 lesions as atypical Spitz tumor. All patients with this diagnosis had a complete excision of the primary tumor with negative margins. Two patients underwent a sentinel lymph node (SLN) biopsy, and in both cases nests of spitzoid melanocytes were found in the subcapsular sinus of the node. A complete lymph node dissection was not performed. All patients are alive and well with no evidence of disease at last follow-up. The follow-up ranged from 2 months to 4 years.
Histopathologic Findings
Histopathologic and immunohistochemical findings are documented in Table 1 and illustrated in Figures 1-6 . All lesions were compound melanocytic proliferations with both junctional and intradermal components. Tumor thickness of all lesions ranged from 1.1 to 6 mm (mean = 2.9 mm; median = 2.5 mm). One tumor was confined to the epidermis and papillary dermis (Clark level III). Thirteen tumors extended into the reticular dermis (Clark level IV) and 2 into the superficial subcutis (Clark level V). All but 2 tumors were amelanotic (no detectable melanin pigment on hematoxylin and eosin-stained sections). Epidermal hyperplasia was common (13 of 17 cases). Two lesions were focally ulcerated (excoriated).
Spitzoid melanocytic proliferations with TPM3 (gene for tropomyosin 3) as the ALK fusion partner included 5 Spitz nevi and 7 Spitz tumors. Mean and median tumor thicknesses of lesions with TPM3-ALK fusions were 3.1 and 2.5 mm, respectively. All tumors of this series displayed a characteristic plexiform growth pattern of intersecting fascicles of predominantly fusiform melanocytes in the dermis ( Figs. 1-4 , Table 1 ). The nuclei showed smooth nuclear contours and a slightly vesicular chromatin pattern. Marked pleomorphism was lacking. Two lesions showed prominent dermal sclerosis. Mitoses were absent or rare. Inflammation was absent in 5 and mild in 6 of 11 tumors. One patient with a Spitz tumor harboring a TPM3-ALK fusion underwent an SLN biopsy. A small cluster of spitzoid melanocytes similar in appearance to the primary tumor was found in the subcapsular sinus of the node (Fig. 4 ).
All spitzoid melanocytic proliferations with DCTN1 (gene for dynactin 1) as the ALK fusion partner had been classified as atypical Spitz tumors. Mean and median tumor thicknesses of lesions with DCTN1-ALK fusions were 2.3 and 2.2 mm, respectively. The mitotic rate ranged from 0 to 2/mm 2 (mean = 1/mm 2 ; median = 1/mm 2 ). Whereas 5 lesions showed a plexiform growth of intersecting fascicles of fusiform melanocytes similar to the Spitz tumors with TPM3-ALK fusions, 2 tumors were composed of a predominant large epithelioid cell proliferation with enlarged nuclei and nuclear pleomorphism (Fig. 5 ). These 2 lesions displayed a plexiform growth pattern only focally. Mild inflammation was observed in 5 of 6 tumors and moderate inflammation in 1 case. One patient with a Spitz tumor harboring a DCTN1-ALK fusion underwent an SLN biopsy with detection of microscopic melanocyte clusters in the subcapsular sinus. This lesion was remarkable for a bulbous nodular growth component in the deep dermis/ superficial subcutis (Fig. 6 ). This lesion was analyzed by array comparative genomic hybridization (aCGH), and no copy number gain or loss was detected.
Immunohistochemical Findings
As implied by the case selection, all lesions were immunohistochemically positive for ALK. Immunoreactivity was strong and homogenous through the entire tumor cell population.
Genetic Findings
FISH with a break-apart probe revealed in all cases an ALK rearrangement. Eight lesions were also analyzed by "melanoma-FISH" using probes for 6p, 6q, 6cent, 11q, and 9p. None of the lesions met the FISH criteria for melanoma ( Table 1) . None of the lesions showed homozygous deletions of 9p.
Using quantitative PCR and Sanger sequencing, 2 types of 5 0 fusion partners for ALK were identified: TPM3 ( Fig. 1) and DCTN1 (Fig. 5 ). TPM3-ALK fusions were detected in 11 Spitz lesions (5 Spitz nevi and 6 atypical Spitz tumors). DCTN1-ALK was found in 6 atypical Spitz tumors and resulted from a balanced translocation between homologous copies of chromosome 2.
aCGH was performed retrospectively on lesions from 2 patients. Both patients had undergone SLN biopsy, and microscopic clusters of spitzoid melanocytes were detected in the subcapsular sinus of the node. No chromosomal gains or losses were detected by aCGH in both cases.
DISCUSSION
Sophie Spitz 16 reported in 1948 a series of melanocytic tumors (then termed "melanoma of childhood") composed of spindled or epithelioid melanocytes that developed predominantly in children and adolescents. It subsequently became apparent that these tumors could also arise later in life and that the majority of these neoplasms behaved in an indolent manner, which led to the term "Spitz nevus." [17] [18] [19] Although criteria have been developed to distinguish Spitz nevi from melanoma, it can at times be very difficult or impossible to make a definitive determination by light microscopic analysis alone, which has led to the category of "borderline" Spitz tumors or spitzoid melanocytic neoplasms of uncertain malignant potential. 1, [17] [18] [19] [20] [21] [22] Given the high stakes of making the correct diagnosis, pathologists have explored the use of ancillary genomic and genetic studies to improve diagnostic accuracy. 2, 3, 23 This effort has not only enriched our understanding of the biology of these tumors, but it has also led to practical applications, such as the increasing utilization of aCGH and/or FISH for improved diagnostic accuracy of spitzoid melanocytic neoplasms. 1, 23, 24 Although chromosomal gains or losses cannot be found in most Spitz nevi, as is the case for melanocytic nevi in general, subsets of spitzoid melanocytic neoplasms have been identified with characteristic genomic or genetic aberrations. 2, 25 One example is the sclerosing Spitz nevus, which may carry an increase in 11p and/or an HRAS mutation. 2 Another distinct variant is the large epithelioid Spitz tumor with isolated deletion of 3p and loss of BAP1, which, if present as multiple lesions, may suggest a BAP1 germline mutation and be associated with a cancer syndrome. 26 A recent discovery of cytogenetic abnormalities of spitzoid melanocytic neoplasms is the presence of various types of kinase fusions, involving ROS1, NTRK1, ALK, RET, and BRAF. 10 Current evidence suggests that these fusions occur in a mutually exclusive pattern, do not overlap with HRAS mutations or loss of BAP1, and are found across the biological spectrum of Spitz lesions. These observations are intriguing as they expand the range of distinct genomic aberrations of spitzoid melanocytic neoplasms. In this study, we sought to document the morphologic spectrum associated with Spitz nevi/tumors with ALK rearrangements and to explore a possible association between histopathologic appearance and fusion partner subtype. Spitz nevi/tumors with ALK fusions tended to be polypoid and amelanotic. A plexiform growth of intersecting fascicles of fusiform melanocytes was the most common and characteristic feature. It was seen in all lesions of this series with TPM3-ALK fusions and in 4 of 6 tumors with DCTN1-ALK fusions. Lesions with the latter fusion subtype also included tumors with a higher proportion of large epithelioid melanocytes with nuclear pleomorphism. As we report our findings, we want to emphasize that they are preliminary. A larger number of cases will be necessary for a more comprehensive assessment of the association of phenotype with genotype.
An important question is the potential clinical significance of the type of kinase fusion and prognosis. As the detection of kinase fusions in Spitz tumors is a very recent discovery, there is at this point insufficient knowledge on this issue. Although none of the patients of this series experienced a tumor recurrence, the number of cases is too small, and the currently available follow-up is too short for any meaningful conclusions. However, it may be of interest in this regard to point out that 2 patients of this series underwent an SLN biopsy after a diagnosis of atypical Spitz tumor was made. Small tumor deposits were found in the SLN of both patients. When the primary tumors were analyzed retrospectively by array CGH, no copy number gains or losses were detected. Whereas clinical follow-up of 1 patient is <1 year, the other patient is alive and well 4 years after the excision of the primary Spitz tumor and detection of melanocyte deposits in the SLN. That patient had undergone only an SLN biopsy with no subsequent complete lymph node dissection.
In conclusion, we present herein 17 cases of Spitz nevi/tumors with ALK fusions and compare the histopathologic findings with the fusion partner subtype. A plexiform growth pattern of intersecting fascicles of amelanotic spindle cells was found as the most characteristic feature, especially in tumors with TPM3-ALK fusions, but it was not exclusive. Future studies are needed to determine the strength of the association between the light microscopic appearance of a lesion and the type of kinase fusion and, most importantly, to learn more about the biological and clinical significance of kinase fusions in spitzoid melanocytic neoplasms.
